HC Wainwright reissued their buy rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX – Free Report) in a research note issued to investors on Friday, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biotechnology company’s stock.
Several other research firms have also issued reports on ALDX. StockNews.com lowered shares of Aldeyra Therapeutics from a hold rating to a sell rating in a research report on Wednesday, May 22nd. Oppenheimer reissued an outperform rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, May 6th.
Get Our Latest Research Report on Aldeyra Therapeutics
Aldeyra Therapeutics Stock Up 21.7 %
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Prime Capital Investment Advisors LLC bought a new stake in Aldeyra Therapeutics during the fourth quarter worth about $35,000. SG Americas Securities LLC acquired a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $39,000. NorthRock Partners LLC acquired a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $42,000. Diversified Trust Co acquired a new stake in Aldeyra Therapeutics during the 2nd quarter valued at $41,000. Finally, Kingswood Wealth Advisors LLC bought a new position in Aldeyra Therapeutics in the 1st quarter valued at $49,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
See Also
- Five stocks we like better than Aldeyra Therapeutics
- What is a Bond Market Holiday? How to Invest and Trade
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- What is a Stock Market Index and How Do You Use Them?
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.